New data on clinical decisions in NSCLC patients with uncommon EGFR mutations
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Respiratory Medicine"
DOI: 10.1080/17476348.2017.1267569
Abstract: ABSTRACT Introduction: Non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor (EGFR) mutations together account for approximately 10% of all EGFR mutations. The most common of which being G719X, S768I, L861Q, and exon… read more here.
Keywords: egfr mutations; lux lung; uncommon egfr; new data ... See more keywords
Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program
Sign Up to like & getrecommendations! Published in 2020 at "OncoTargets and therapy"
DOI: 10.2147/ott.s273866
Abstract: Background Post hoc analysis of the LUX-Lung 3 and 6 (LL3/6) Phase III trials showed that tolerability-guided dose-adjustments of afatinib reduced treatment-related adverse events (TRAEs) without affecting progression-free survival (PFS) in patients with epidermal growth… read more here.
Keywords: lux lung; dose reduction; dose adjustments; tolerability guided ... See more keywords